Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Nature Medicine

• Publication date

  2004-11-21

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nm1146PMID 15558054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels.

  2004cited by this paper
• p 300 regulates p 53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA p 21 levels

  2004cited by this paper
• p53 has a direct apoptogenic role at the mitochondria.

  2003cited by this paper
• iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human

  2003cited by this paper
• Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

  2003cited by this paper
• Parc: a cytoplasmic anchor for p53.

  2003cited by this paper
• Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300

  2003cited by this paper
• Slow Tight Binding Inhibition of Proteinase K by a Proteinaceous Inhibitor

  2003cited by this paper
• Activation of the p53 tumor suppressor protein.

  2002cited by this paper
• The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

  2002cited by this paper
• Mdm-2 binding and TAFII31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21

  2002cited by this paper
• Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors

  2002cited by this paper
• The IARC TP53 database: New online mutation analysis and recommendations to users

  2002cited by this paper
• Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

  2001cited by this paper
• p53 Latency

  2001cited by this paper
• Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.

  2001cited by this paper
• p53 Latency: C-Terminal Domain Prevents Binding of p53 Core to Target but not to Nonspecific DNA Sequences

  2001cited by this paper
• Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.

  2001cited by this paper
• Exogenous wt‐p53 protein is active in transformed cells but not in their non‐transformed counterparts: implications for cancer gene therapy without tumor targeting

  2000cited by this paper
• Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo

  2000cited by this paper
• Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA

  2000cited by this paper
• A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

  2000cited by this paper
• DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

  1999cited by this paper
• Transient excess of MYC activity can elicit genomic instability and tumorigenesis.

  1999cited by this paper
• Control of cell growth by c-Myc in the absence of cell division.

  1999cited by this paper
• CDC25A Phosphatase Is a Target of E2F and Is Required for Efficient E2F-Induced S Phase

  1999cited by this paper
• Specific binding of proinsulin C-peptide to human cell membranes.

  1999cited by this paper
• Epstein – Barr virus nuclear protein 2 interacts with p 300 , CBP , and PCAF histone acetyltransferases in activation of the LMP 1 promoter

  1999cited by this paper
• Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• A matter of life and cell death.

  1998cited by this paper
• Signaling to p53: breaking the MDM2-p53 circuit.

  1998cited by this paper
• p300/MDM2 complexes participate in MDM2-mediated p53 degradation.

  1998cited by this paper
• Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

  1997cited by this paper
• Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

  1997cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins (*)

  1996cited by this paper
• The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.

  1996cited by this paper
• Regulation of Mutant p53 Temperature-sensitive DNA Binding*

  1996cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• Solution structure of the tetrameric minimum transforming domain of p53

  1995cited by this paper
• Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms

  1995cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

  1994cited by this paper
• Suppression of human colorectal carcinoma cell growth by wild-type p53.

  1990cited by this paper
• INHIBITING THE p 53 – MDM 2 INTERACTION : AN IMPORTANT TARGET FOR CANCER THERAPY

  year unknowncited by this paper

• CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment.

  2026cites this paper
• Targeting the UPR with Small Molecules: Emerging Strategies for Immune Regulation

  2026cites this paper
• TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches

  2026cites this paper
• Ambiguous Role of p53 in Transcription-Dependent Tumor Cell Death

  2026cites this paper
• The Stetter reaction: modern methodologies and useful applications in total synthesis of natural products and drugs

  2026cites this paper
• Intrinsically disordered proteins and liquid-liquid phase separation in drug discovery.

  2026cites this paper
• Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration

  2025cites this paper
• NIMA-related kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting.

  2025cites this paper
• Pathways to precision medicine in cervical cancer: a comprehensive review of small molecule inhibitors, biomarkers and computational approaches

  2025cites this paper
• Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma

  2025cites this paper
• Natural products that target p53 for cancer therapy

  2025cites this paper
• Identification of GBP6 as a potential prognostic biomarker in esophageal carcinoma by integrated bioinformatics analysis and experiment validation

  2025cites this paper
• MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

  2025cites this paper
• Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53

  2025cites this paper
• HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency

  2025cites this paper
• Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma

  2024cites this paper
• Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies

  2024cites this paper
• TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

  2024cites this paper
• The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer

  2024cites this paper
• BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.

  2024cites this paper
• Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)

  2024cites this paper
• Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

  2024cites this paper
• The role of ubiquitination in health and disease

  2024cites this paper
• The Ubiquitin Tale: Current Strategies and Future Challenges.

  2024cites this paper
• MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• Astilbin Induces Apoptosis in Oral Squamous Cell Carcinoma through p53 Reactivation and Mdm-2 Inhibition

  2024cites this paper
• Multicomponent synthesis of chromophores – The one-pot approach to functional π-systems

  2023cites this paper
• A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

  2023cites this paper
• The Development of p53-Targeted Therapies for Human Cancers

  2023cites this paper
• Pellino 3 promotes the colitis‐associated colorectal cancer through suppression of IRF4‐mediated negative regulation of TLR4 signalling

  2023cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.

  2023cites this paper
• Pyrimido[4,5-b]indole derivatives bearing 1,2,4-oxadiazole moiety as MDM2 inhibitor candidates in cancer treatment.

  2023cites this paper
• Synthesis and biological assessment of indole derivatives containing penta-heterocycles scaffold as novel anticancer agents towards A549 and K562 cells

  2023cites this paper
• Role of p53 in breast cancer progression: An insight into p53 targeted therapy

  2023cites this paper
• Cellular senescence in glioma

  2023cites this paper
• Targeting p53 for neuroinflammation: New therapeutic strategies in ischemic stroke

  2023cites this paper
• Nucleolar phosphoprotein modifications as a marker of apoptosis induced by RITA treatment.

  2023cites this paper
• Tripartite motif containing 69 elicits ERK2-dependent EYA4 turnover to impart pancreatic tumorigenesis

  2023cites this paper
• Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

  2023cites this paper
• Transcription factor-target gene regulatory network analysis in human lung adenocarcinoma

  2023cites this paper
• E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities.

  2023cites this paper
• Mild oxidative stress protects against chemotherapy-induced hair loss

  2023cites this paper
• Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein

  2023cites this paper
• p53 gene mutations among patients involved with breast cancer: types of detection

  2023cites this paper
• The RUNX Family, a Novel Multifaceted Guardian of the Genome

  2023cites this paper
• [RITA selectively inhibits proliferation of BAP1-deficient cutaneous melanoma cells in vitro].

  2023cites this paper
• OTT_A_342292 23..30

  2022cites this paper
• Role of p53 in Human Cancers

  2022cites this paper
• Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments

  2022influential citation
• Future Developments in the Treatment of AL Amyloidosis

  2022cites this paper
• Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer

  2022cites this paper
• p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies.

  2022cites this paper
• Investigation of the effects of the small molecule RITA in pediatric acute lymphoblastic leukemia

  2022influential citation
• The roles of E3 ligases in Hepatocellular carcinoma.

  2022cites this paper
• Agents Targeting Apoptosis Take Center Stage in the Battle against Cancer

  2022cites this paper
• Mechanism of apoptosis activation by curcumin rescued mutant p53Y220C in human pancreatic cancer.

  2022cites this paper
• Reactivation of p53 by RITA Induces Apoptosis in Human Oral Squamous Cell Carcinoma Cells

  2022cites this paper
• Interaction among noncoding RNAs, DNA damage reactions, and genomic instability in the hypoxic tumor: is it therapeutically exploitable practice?

  2022cites this paper
• Drugging p53 in cancer: one protein, many targets

  2022cites this paper
• Decreased DNA Damage and Improved p53 Specificity of RITA Analogs

  2022cites this paper
• Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.

  2022cites this paper
• Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness

  2022cites this paper
• A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer

  2022cites this paper
• Should mutant TP53 be targeted for cancer therapy?

  2022cites this paper
• Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

  2022cites this paper
• Cruciferous vegetables as a treasure of functional foods bioactive compounds: Targeting p53 family in gastrointestinal tract and associated cancers

  2022cites this paper
• Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

  2021cites this paper
• PPM1D Is a Therapeutic Target in Childhood Neural Tumors

  2021influential citation
• Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2

  2021cites this paper
• Real-Time Spatial and Temporal Analysis of the Translocation of the Apoptosis-Inducing Factor in Cells.

  2021cites this paper
• Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.

  2021cites this paper
• Targeting mutant p53 for cancer therapy: direct and indirect strategies

  2021cites this paper
• E3 ubiquitin ligases: styles, structures and functions

  2021cites this paper
• An HIV-induced mechanism for T cell quiescence and proviral latency

  2021influential citation
• Therapeutic targeting of SETD2-deficient cancer cells with the small-molecule compound RITA

  2021cites this paper
• Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics.

  2021cites this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cites this paper
• Stability of p53 oligomers: Tetramerization of p53 impinges on its stability.

  2021cites this paper
• Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy

  2021cites this paper
• The roles and regulation of MDM2 and MDMX: it is not just about p53

  2021cites this paper
• Molecular pathways of apoptotic cell death

  2021cites this paper
• Autophagic Organelles in DNA Damage Response

  2021cites this paper
• Intrinsically disordered proteins and biomolecular condensates as drug targets.

  2021cites this paper
• Pathway-Directed Therapy in Multiple Myeloma

  2021cites this paper
• The p53 pathway in vasculature revisited: a therapeutic target for pathological vascular remodeling?

  2021cites this paper
• More Than Just Cleaning: Ubiquitin-Mediated Proteolysis in Fungal Pathogenesis

  2021cites this paper
• Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

  2021cites this paper
• Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

  2021cites this paper
• TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

  2021cites this paper
• The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

  2021cites this paper
• HPV-induced cancers: preclinical therapeutic advancements

  2021cites this paper
• Regulation of p53 by E3s

  2021cites this paper
• Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

  2021cites this paper
• 2-[(4-Hydroxybenzyl) Amino] Phenol (HBAP) Restores the Mutated p53 to the Level Similar to That of Wild-Type p53 Protein and Inhibits Breast Cancer Growth in vivo to by Inducing Tumor Cells Apoptosis

  2020cites this paper
• Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases

  2020cites this paper
• The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing

  2020influential citation
• Prion-like p53 amyloids in cancer.

  2020cites this paper
• Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer’s disease mouse model

  2020cites this paper